Chardan Capital Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $22

Benzinga Newsdesk www.benzinga.com Neutral 62.6%

Neg 0% Neu 62.6% Pos 0%

Chardan Capital analyst Geulah Livshits initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $22.